IL17A and Parkinson disease: Levels of IL-17A in cerebrospinal fluid (CSF) and plasma are significantly increased in patients with MS, AD, and PD, and the expression levels are related to the severity and progress of diseases (Gu et al., 2013; Zhang et al., 2013; Kostic et al., 2014).